One and one-half percent of human sera from patients seen at a clinic for treatment of cancer contai dA antibodies to the nuclei of chick kidney cells by indirect immunofluorescence tests. In the group of sera containing antinuclear antibodies, the geometric mean titer to Epstein-Barr virus (EBV) capsid antigen was significantly elevated. Sera obtained from normal adults or from patients with similar histological types of tumnors that possessed no antinuclea antibodies contained lower levels of anti-EBV antibodies. The elevated titers to EBV were correlated with the presence or absence of antinuclear antibodies and not with a particular type or site of neoplastic disease. Immunofluorescence tests. Cells were grown or smeared (for HR-1K cells) on cover slips, washed three times with phosphate-buffered saline (PBS), air dried, and fixed with acetone for 10 min. Fixed slides were stored at -80 C. Sera were diluted 1:4 before testing for ANA. Fourfold dilutions (initial, 1:10) were used to titrate antibodies to EBV. A semimicro procedure for indirect immunofluorescence (26) was used. In brief, cover slips were incubated with the serum for 1 h at 37 C. After washing the cover slip with PBS, appropriately diluted goat antihuman immunoglobulin G, H-and L-chain specific (Hyland, Costa Mesa, Calif.), was added and incubated for an additional hour at 37 C. The preparations were then washed three times with PBS, dipped in distilled water, blotted dry, and mounted in glycerol-PBS (1:1).
tiansform human cells in vitro 13D), we found a small percentage of sera from cancer patients that contained antibodies to the nuclei of chick kidney (CK) cells. Antinuclear antibodies (ANA) have been found in sera from individuals with either infectious mononucleosis (IM) (22) or nasopharyngeal carcinoma (NPC) (33) , both of which are associated with Epstein-Barr virus (EBV) (8) . ANA, however, have not been demonstrated in sera from cases of Burkitt's lymphoma (BL) (34) , the African lymphoma consistently producing high antibody titers to EBV. Patients with diseases characterized by immunological malfunction, such as systemic lupus erythematosus (SLE) (9, 10) or sarcoidosis (19, 31) , also produce elevated titers of antibodies to EBV capsid antigen. We therefore wished to determine whether cancer patients with obvious immunological disorders, as evidenced bv the presence of ANA to CK nuclei, also possess increased antibody titers to this EBV antigen when compared with individuals with a similar type of tumor but without ANA.
MATERIALS AND METHODS Cells. Primary CK cells were prepared by the method of Anderson et al. (2) . The HR-1K lymphoblastoid cell line (18) derived from the P3J line of Burkitt's lymphoma cells was used as the source of EBV capsid antigen (13) . The BALB/c 3T3 cell line of murine fibroblasts (30) was used to confirm the presence of ANA in human sera. The preparation of CK cells containing CELO T antigen was described (1 Anti-EBV titers in sera from ANA-positive cancer patients with similar histological types of tumors were then compared ( Table 2) . Approximately 68% of sera from ANA-positive groups had elevated anti-EBV titers. Only 28%k of ANA-negative sera possessed elevated anti-EBV titers. Although the GMT of ANA-positive sera were consistently higher than those of ANA-negative sera, only ANA-positive sera from adenocarcinoma patients had a significantly (P < 0.005) higher GMT (1:278) than was found in ANA-negative sera either from other adenocarcinoma patients (1:31) or from patients with other malignant diseases combined (1:48) . The distribution of elevated titers in ANA-positive sera from patients with adenocarcinomas was, of course, also significantly increased (X2, P < 0.05) from that in ANA-negative sera from adenocarcinomas. The presence of ANA and elevated anti-EBV titers in sera from cases of adenocarcinoma were unrelated to any specific tissue origin of the malignant growth.
When data were analyzed according to site of tumor without regard to histological type (Table 3), groups of ANA-positive sera always possessed higher GMT. However, differences in GMT between ANA-positive and ANA-negative groups with the same tumor site were statistically significant only in patients with tumors of the gastrointestinal or genitourinary tracts. ' GMT is significantly elevated when compared with normal sera (t test, P < 0.01) or ANA-negative sera from tumorous patients (t test, P < 0.005). GMT is significantly lower than sera from BL patients (t test, p < 0.01). GMT is significantly elevated when compared with ANA-negative sera from adenocarcinoma patients (t test, P < 0.005) or to all ANA-negative sera combined (t test, P < 0.05). GMT is significantly elevated when compared with ANA-negative sera from patients with gastrointestinal tumors (t test, P < 0.025).
bGMT is significantly elevated when compared with ANA-negative sera from patients with genitourinary tumors (t test, P < 0.005) or with all ANA-negative sera combined (t test, P < 0.005).
DISCUSSION
An increase in both the percentage of positive sera and titer of antibodies to EBV, the etiological agent of IM (15, 27) , has also been associated with a variety of malignant diseases such as BL (14) , NPC (6, 17) , HD (20, 24) , and lymphocytic lymphomas and leukemias (16, 21, 23, 25) . Sera from other neoplastic conditions have not been reported to have elevated titers to EBV. The highest titers of antibody are present in patients with BL and NPC; intermediate titers are present in IM and the remaining malignant diseases (16, 23) . No increases (7, 12) in anti-EBV titers were reported in other malignant diseases of lymphoproliferative, carcinomatous, or sarcomatous origin.
Since patients with IM or NPC (22, 33) , both associated with EBV, may produce ANA, we studied anti-EBV titers in cancer patients with or without ANA to nuclei of CK cells. The GMT of antibodies in sera from patients negative for ANA was similar to that in normal sera. In contrast, sera from patients who produced ANA showed elevated titers to EBV. The GMT obtained in this study correspond to those found in patients with IM, HD, SLE, (9, 10), or sarcoidosis (19, 31) . The elevated titers appeared to be associated with the presence of ANA since: (i) sera of normal individuals produced GMT similar to those of cancer patients lacking ANA; (ii) the GMT of ANA-positive sera from patients with similar histological types of tumors were consistently elevated; and (iii) higher GMT were found in sera containing ANA when compared with the GMT of sera from ANA-negative patients with tumors of the same organ.
The elevated titers in ANA-positive sera were not the result of age differences between cancer patients and normal controls. (9) found no correlation between presence and titer of ANA and elevated anti-EBV titers in individual patients with SLE.
The increase in anti-EBV titers of sera containing ANA to CK cells could result from (i) activation of latent EBV; (ii) an increased susceptibility to EBV; (iii) cross-reactivities with antigens of other herpesviruses (11, 28) ; or (iv) a nonspecific response of a malfunctioning immune system. ANA have been shown to appear in mice after infection with type C leukemia viruses (4) . Although ANA may be found in sera from cases of IM and NPC, BL patients have not been shown to produce ANA (34) , suggesting that ANA is not directly related to infection by EBV. Since intermediately elevated titers to EBV are also present in a bacterial disease, lepromatous leprosy, in which cellmediated immunity is depressed (29), we assume that a nonspecific immunological disorder characterized by ANA formation is also responsible for the elevated EBV titers. Serological studies utilizing other herpesviruses as antigen should indicate whether or not an elevated titer is specific for only the one human herpesvirus (EBV) or represents a general immunological stimulation to latent herpesviruses. 
